Strengthening the holding company structure and pursuing economies of scale and synergies
First written in FY2016. 11 of 22 entries say "Restated". Latest entry: FY2026.
25 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Specifically, the company prepared the second and third projects in its senior-oriented for-sale condominium business, entered the overseas ODA business, expanded its healthcare information solutions business, and promoted the reorganization and integration of the Group, centered on the キングラン Group, dispensing pharmacy business, and food service business.」
Under portfolio management, concrete progress was made in new businesses, overseas businesses, healthcare information businesses, and the reorganization and integration of the キングラン Group and other businesses. - FY2026-H1AdvancedAnnual report
「During the current interim consolidated accounting period, ㈱テックインターナショナル and デルフィア㈱ were included in the scope of consolidation following the acquisition of their shares, while マスターズフォレスト㈱ was included following its establishment.」
The acquisition of テックインターナショナル and デルフィア, and the establishment and consolidation of マスターズフォレスト, expanded the Group foundation centered on the holding company. - FY2025AdvancedAnnual report
「In addition, five companies within the business were reorganized and integrated on 1 October 2024.」
Five companies in the Medical Supply business and 2 companies in the Life Care business were reorganized and integrated, advancing organizational restructuring aimed at integration and greater efficiency within the Group. - FY2025-H1AdvancedAnnual report
「During the current interim consolidated accounting period, シップヘルスケアファーマシー東日本㈱, a consolidated subsidiary, absorbed ㈲Ｃ.Ｍ.Ｊ and ㈲フレンズ, which had also been consolidated subsidiaries. In addition, ㈱ＭＯＮＡＫＡ was included in the scope of consolidation following the acquisition of its shares.」
The absorption merger between consolidated subsidiaries and the acquisition and consolidation of ＭＯＮＡＫＡ were carried out, making concrete progress in restructuring and expanding the Group foundation centered on the holding company. The realization of synergies itself was not stated. - FY2024-Q3RestatedAnnual report
「In addition, the performance of the キングラン Group, which joined the Group in July 2022, contributed from the cumulative first quarter of the current fiscal year.」
The キングラン Group continues to contribute to performance, reconfirming the consolidated effects following the expansion of the Group foundation. - FY2024-Q2RestatedAnnual report
「In addition, the performance of the キングラン Group, which joined the Group in July of the previous year, contributed from the cumulative first quarter of the current fiscal year.」
The キングラン Group continues to contribute to performance, reconfirming the consolidated effects and synergies following the expansion of the Group foundation. - FY2024-Q1RestatedAnnual report
「In addition, the performance of the キングラン Group, which joined the Group in July of the previous year, contributed from the cumulative first quarter of the current fiscal year.」
The company explained that the performance of the キングラン Group, which became a subsidiary in the previous fiscal year, contributed from the current quarter, confirming the contribution to performance following the expansion of the Group foundation. - FY2023-Q2RestatedAnnual report
「We believe that leveraging the company's product capabilities and broad customer base will create synergies across the Group, including in the Total Pack Produce business, and lead to further enhancement of corporate value.」
The explanation that キングラン's product capabilities and customer base would be used to create synergies across the Group has been reconfirmed following its conversion into a subsidiary. - FY2023-Q1AdvancedAnnual report
「In accordance with the share transfer agreement, the company acquired the common shares of キングラン株式会社 on 1 July 2022 and made it a subsidiary.」
The acquisition of キングラン株式会社 and its conversion into a subsidiary was completed on 1 July 2022. The post-acquisition voting rights ratio was 98.0%, marking concrete progress in expanding the Group foundation centered on the holding company and pursuing synergies. - FY2022AdvancedAnnual report
「By leveraging the company's product capabilities and broad customer base, synergies are expected to be created across the Group, including in the Total Pack Produce business, leading to further enhancement of corporate value.」
The acquisition of キングラン株式会社 as a subsidiary was presented as a concrete expansion initiative to connect its product capabilities and customer base with synergies across the Group. The share acquisition was scheduled for 1 July 2022, with a post-acquisition voting rights ratio of 98.0%. - FY2021RestatedAnnual report
「The aim is to further improve services for customers by expanding the scale of the business and its business domains, as well as realizing synergies through more efficient management and other measures.」
The annual report also confirms the policy behind the absorption merger of 小西共和ホールディング and 共和医理器, with 小西医療器 as the surviving company, namely to expand the business scale and domains and realize synergies through greater efficiency. - FY2021-Q3AdvancedAnnual report
「To further improve services for customers by expanding the scale of the business and its business domains, as well as realizing synergies through more efficient management and other measures.」
The absorption merger of 小西共和ホールディング and 共和医理器 by 小西医療器 was carried out, advancing the pursuit of synergies through expanded business scale and domains and greater management efficiency as a concrete organizational restructuring initiative. - FY2021-Q2RestatedAnnual report
「In the Medical Supply business, performance remained solid through collaboration within the Group and greater management efficiency, despite the impact of reimbursement price revisions, while」
The policy of operating the business through collaboration within the Group and greater management efficiency has been reconfirmed. - FY2020RestatedAnnual report
「We will further develop healthcare engineering, which coordinates entire healthcare institutions, together with the consultation services that make this possible, as our unique business model that is second to none. We will lead the expansion of new projects and synergies among Group companies, while also seeking to develop recurring-revenue businesses.」
The policy of pursuing a unique model, new projects, synergies among Group companies, and recurring-revenue businesses based on the holding company structure has been reiterated. - FY2020-Q2RestatedAnnual report
「The Medical Supply business performed steadily through collaboration with the Total Pack Produce business, the acquisition of contracts for new SPD facilities, and more efficient operation of SPD facilities. There was also front-loaded demand for consumables ahead of the consumption tax increase. As a result, revenue was ¥160,607 million, up 16.8% from the cumulative second quarter of the previous consolidated fiscal year, and segment profit (operating profit) was ¥2,455 million, up 43.3%.」
The Medical Supply business is described as having performed steadily through collaboration with the Total Pack Produce business, the acquisition of contracts for new SPD facilities, and more efficient SPD operations. - FY2020-Q1RestatedAnnual report
「In the Medical Supply business, securing profits remains difficult due to the impact of last year's reimbursement price revisions. However, performance was broadly in line with the plan through collaboration within the Group and greater operating efficiency.」
The policy of operating the Medical Supply business broadly in line with the plan through collaboration within the Group and greater operating efficiency has been reconfirmed. - FY2018RestatedAnnual report
「Continuous kaizen activities became established across the Group companies and began to produce results. Improvements in occupancy rates in the Life Care business and higher profitability in the dispensing pharmacy business also contributed, enabling the company to achieve its initial plan.」
The direction of embedding cross-group improvement activities across the Group companies and realizing collaboration and synergies among the businesses has been reconfirmed. - FY2017-Q2RestatedAnnual report
「Revenue and profit increased, primarily due to contributions from the newly consolidated companies following the management integration with 小西共和ホールディング株式会社.」
The management integration with 小西共和ホールディング continues to contribute through the performance of the newly consolidated companies. - FY2017-Q1AdvancedAnnual report
「The purpose of this management integration is to establish a position as a leader in Japan's healthcare industry by combining the management resources that the two companies have cultivated independently, and to become a company highly valued by all stakeholders.」
The management integration progressed to the implementation stage, with 小西共和ホールディング and its 4 subsidiaries being consolidated, strengthening the Group foundation centered on the holding company. - FY2016First statedAnnual report
「The Group views this environment as a business opportunity and will further strengthen the business foundation of its holding company structure, pursue additional economies of scale, realize synergies, and expand into new fields.」
Measures to advance economies of scale, collaboration among Group companies, and expansion into new fields based on the holding company structure.